Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...

Icotrokinra, formerly known as JNJ-2113, is an investigational oral peptide that blocks the interleukin (IL)-23 receptor, which plays a significant role in the pathogenesis of moderate to severe ...

The study was conducted among patients with plaque psoriasis affecting special areas such as the scalp, genitals and/or hands ...

Discover why analysts are bullish on Arcutis Biotherapeutics after strong Q3 results, despite recent market fluctuations in ...

MALVERN, Pa., Nov. 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI ) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream ...

Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

"This is the first time I'm really talking about it publicly… but you just get that 'aha' moment where you realize 'I wasn't put in this position to not utilize my voice and my platform for good." La ...

Medically reviewed by Doru Paul, MD To confirm a psoriasis diagnosis, your healthcare provider will check your skin and scalp ...